{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:37:55Z","timestamp":1761507475352,"version":"build-2065373602"},"reference-count":13,"publisher":"CSIRO Publishing","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":556,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO-US-276-5866"],"award-info":[{"award-number":["CO-US-276-5866"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC\/TDF) is generally well-tolerated, although treatment-related adverse events have been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report two cases of persons using FTC\/TDF PrEP who had acute neuralgia in a Chinese PrEP demonstration trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neurological symptoms subsided upon treatment discontinuation. Symptoms were reported as similar to one case\u2019s previous experiences with dolutegravir (DTG)\u00a0+\u00a0FTC\u00a0+\u00a0tenofovir alafenamide (TAF) (for PEP), leading to permanent discontinuation of PrEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Acute facial neuralgia appears to be a rare idiosyncratic adverse event to FTC\/TDF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh23129","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T18:34:15Z","timestamp":1706466855000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute facial neuralgia related to initiation of emtricitabine\/tenofovir for HIV PrEP: a report of two cases in a PrEP demonstration trial"],"prefix":"10.1071","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7012-5986","authenticated-orcid":true,"given":"Zhuoheng","family":"Yin","sequence":"first","affiliation":[{"name":"ADermatology Hospital Southern Medical University, Guangzhou, China."},{"name":"BUniversity of North Carolina Project-China, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayner Kay Jin","family":"Tan","sequence":"additional","affiliation":[{"name":"BUniversity of North Carolina Project-China, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-1181","authenticated-orcid":true,"given":"Joseph D.","family":"Tucker","sequence":"additional","affiliation":[{"name":"BUniversity of North Carolina Project-China, Guangzhou, China."},{"name":"CClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanmin","family":"Li","sequence":"additional","affiliation":[{"name":"DInfectious Disease Center, Guangzhou Eighth People\u2019s Hospital, Guangzhou Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renslow","family":"Sherer","sequence":"additional","affiliation":[{"name":"ESection of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, Chicago, IL, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[{"name":"DInfectious Disease Center, Guangzhou Eighth People\u2019s Hospital, Guangzhou Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-707X","authenticated-orcid":true,"given":"Weiming","family":"Tang","sequence":"additional","affiliation":[{"name":"ADermatology Hospital Southern Medical University, Guangzhou, China."},{"name":"BUniversity of North Carolina Project-China, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"issue":"9","key":"2025102615330863100_R1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2025102615330863100_R2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s11606-020-05651-2","article-title":"On-demand oral pre-exposure prophylaxis with tenofovir\/emtricitabine: what every clinician needs to know.","volume":"35","author":"Saberi","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2025102615330863100_R3","unstructured":"Centers for Disease Control and Prevention. How effective is PrEP? 2022. Available at https:\/\/www.cdc.gov\/hiv\/basics\/prep\/prep-effectiveness.html [cited 26 October 2023]"},{"key":"2025102615330863100_R4","unstructured":"World Health Organization. Global state of PrEP; 2022. Available at https:\/\/www.who.int\/groups\/global-prep-network\/global-state-of-prep [cited 28 October 2022]"},{"key":"2025102615330863100_R5","unstructured":"Gilead Sciences. Science and medicine; 2023. Available at https:\/\/www.gilead.com\/science-and-medicine\/medicines [cited 20 June 2023]"},{"issue":"2","key":"2025102615330863100_R6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/QAI.0000000000001566","article-title":"Changes in kidney function associated with daily tenofovir disoproxil fumarate\/emtricitabine for HIV preexposure prophylaxis use in the United States demonstration project.","volume":"77","author":"Tang","year":"2018","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"27","key":"2025102615330863100_R7","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2025102615330863100_R8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial.","volume":"61","author":"Mulligan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025102615330863100_R9","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14117-5","article-title":"Co-creation using crowdsourcing to promote PrEP adherence in China: study protocol for a stepped-wedge randomized controlled trial.","volume":"22","author":"Sha","year":"2022","journal-title":"BMC Public Health"},{"key":"2025102615330863100_R10","doi-asserted-by":"publisher","DOI":"10.1177\/2325958218760846","article-title":"Acute trigeminal neuralgia associated with initiation of emtricitabine\/tenofovir for HIV pre-exposure prophylaxis.","volume":"17","author":"Van Slyke","year":"2018","journal-title":"J Int Assoc Provid AIDS Care JIAPAC"},{"key":"2025102615330863100_R11","unstructured":"eHealthMe. Truvada and Trigeminal neuralgia - a phase IV clinical study of FDA data. 2023. Available at https:\/\/www.ehealthme.com\/ds\/truvada\/trigeminal-neuralgia\/ [accessed 21 January 2024]"},{"key":"2025102615330863100_R12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IMCRJ.S52015","article-title":"Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya.","volume":"6","author":"Owino","year":"2013","journal-title":"Int Med Case Rep J"},{"issue":"1","key":"2025102615330863100_R13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of HIV medications.","volume":"10","author":"Margolis","year":"2014","journal-title":"J Med Toxicol"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH23129\/587736\/sh23129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH23129\/587736\/sh23129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:33:16Z","timestamp":1761507196000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/21\/1\/SH23129\/82197\/Acute-facial-neuralgia-related-to-initiation-of"}},"subtitle":[],"editor":[{"given":"Jason","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,8]]}},"URL":"https:\/\/doi.org\/10.1071\/sh23129","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"type":"print","value":"1448-5028"},{"type":"electronic","value":"1449-8987"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"article-number":"SH23129"}}